You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCandesartan
Accession NumberDB00796  (APRD00420)
TypeSmall Molecule
GroupsApproved
DescriptionCandesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Structure
Thumb
Synonyms
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
Blopress
Candesartan cilexetil
CV-11974
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-candesartantablet32 mgoralAccord Healthcare Inc2012-02-16Not applicableCanada
Ach-candesartantablet4 mgoralAccord Healthcare Inc2012-02-16Not applicableCanada
Ach-candesartantablet8 mgoralAccord Healthcare Inc2012-02-16Not applicableCanada
Ach-candesartantablet16 mgoralAccord Healthcare Inc2012-02-16Not applicableCanada
Act Candesartantablet32 mgoralActavis Pharma Company2011-11-30Not applicableCanada
Act Candesartantablet4 mgoralActavis Pharma Company2011-11-30Not applicableCanada
Act Candesartantablet8 mgoralActavis Pharma Company2011-11-30Not applicableCanada
Act Candesartantablet16 mgoralActavis Pharma Company2011-12-15Not applicableCanada
Atacandtablet8 mg/1oralCarilion Materials Management1998-09-14Not applicableUs
Atacandtablet4 mg/1oralAstra Zeneca Lp1998-09-14Not applicableUs
Atacandtablet32 mgoralAstrazeneca Canada Inc2008-07-17Not applicableCanada
Atacandtablet16 mg/1oralPhysicians Total Care, Inc.2000-11-21Not applicableUs
Atacandtablet4 mgoralAstrazeneca Canada Inc2005-06-28Not applicableCanada
Atacandtablet8 mg/1oralAstra Zeneca Lp1998-09-14Not applicableUs
Atacandtablet16 mg/1oralbryant ranch prepack1998-09-14Not applicableUs
Atacandtablet16 mg/1oralCardinal Health2009-11-11Not applicableUs
Atacandtablet16 mg/1oralAstra Zeneca Lp1998-09-14Not applicableUs
Atacandtablet4 mg/1oralbryant ranch prepack1998-09-14Not applicableUs
Atacandtablet32 mg/1oralAstra Zeneca Lp1998-09-14Not applicableUs
Atacandtablet4 mg/1oralCarilion Materials Management1998-09-14Not applicableUs
Atacand Tab 16 mgtablet16 mgoralAstrazeneca Canada Inc1998-12-07Not applicableCanada
Atacand Tab 8mgtablet8 mgoralAstrazeneca Canada Inc1998-12-07Not applicableCanada
Auro-candesartantablet8 mgoralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-candesartantablet16 mgoralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-candesartantablet32 mgoralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-candesartantablet4 mgoralAuro Pharma Inc2015-12-02Not applicableCanada
Bio-candesartantablet4 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-candesartantablet8 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-candesartantablet16 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-candesartantablet32 mgoralBiomed PharmaNot applicableNot applicableCanada
Candesartantablet16 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Candesartantablet16 mgoralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
Candesartantablet32 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Candesartantablet32 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Candesartantablet4 mgoralSanis Health Inc2012-07-20Not applicableCanada
Candesartantablet4 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Candesartantablet8 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Candesartantablet8 mgoralSanis Health Inc2012-07-20Not applicableCanada
Candesartantablet32 mgoralPro Doc Limitee2014-06-05Not applicableCanada
Candesartantablet4 mgoralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
Candesartantablet8 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Candesartantablet8 mgoralPro Doc Limitee2012-02-02Not applicableCanada
Candesartantablet32 mgoralSanis Health Inc2015-01-12Not applicableCanada
Candesartantablet4 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Candesartantablet16 mgoralSanis Health Inc2012-07-20Not applicableCanada
Candesartantablet16 mgoralPro Doc Limitee2012-02-02Not applicableCanada
Candesartantablet8 mgoralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
Candesartantablet16 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Candesartan Cilexetiltablet4 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan Cilexetiltablet32 mg/1oralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan Cilexetiltablet32 mg/1oralAmerican Health Packaging2015-09-01Not applicableUs
Candesartan Cilexetiltablet4 mg/1oralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan Cilexetiltablet8 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan Cilexetiltablet16 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan Cilexetiltablet8 mg/1oralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan Cilexetiltablet32 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Candesartan Cilexetiltablet16 mg/1oralPar Pharmaceutical Inc.2013-05-21Not applicableUs
Candesartan Cilexetiltablet8 mg/1oralAmerican Health Packaging2015-09-01Not applicableUs
Dom-candesartantablet32 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-candesartantablet8 mgoralDominion Pharmacal2013-10-16Not applicableCanada
Dom-candesartantablet4 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-candesartantablet16 mgoralDominion PharmacalNot applicableNot applicableCanada
Ipg-candesartantablet16 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-candesartantablet32 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-candesartantablet4 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-candesartantablet8 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-candesartantablet16 mgoralJamp Pharma Corporation2012-06-11Not applicableCanada
Jamp-candesartantablet32 mgoralJamp Pharma Corporation2012-06-11Not applicableCanada
Jamp-candesartantablet4 mgoralJamp Pharma Corporation2012-06-29Not applicableCanada
Jamp-candesartantablet8 mgoralJamp Pharma Corporation2012-06-11Not applicableCanada
Mylan-candesartantablet32 mgoralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Mylan-candesartantablet4 mgoralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Mylan-candesartantablet8 mgoralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Mylan-candesartantablet16 mgoralMylan Pharmaceuticals Ulc2012-02-09Not applicableCanada
Ntp-candesartantablet32 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-candesartantablet8 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-candesartantablet16 mgoralTeva Canada LimitedNot applicableNot applicableCanada
PMS-candesartantablet32 mgoralPharmascience Inc2012-08-06Not applicableCanada
PMS-candesartantablet4 mgoralPharmascience Inc2012-08-06Not applicableCanada
PMS-candesartantablet8 mgoralPharmascience Inc2012-08-06Not applicableCanada
PMS-candesartantablet16 mgoralPharmascience Inc2012-08-06Not applicableCanada
Priva-candesartantablet4 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-candesartantablet8 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-candesartantablet16 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-candesartantablet32 mgoralPharmapar IncNot applicableNot applicableCanada
Q-candesartantablet8 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-candesartantablet32 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-candesartantablet16 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-candesartantablet4 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-candesartantablet16 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-candesartantablet32 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-candesartantablet4 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-candesartantablet8 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Riva-candesartantablet8 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-candesartantablet16 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-candesartantablet32 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-candesartantablet4 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Sandoz Candesartantablet32 mgoralSandoz Canada Incorporated2012-11-23Not applicableCanada
Sandoz Candesartantablet8 mgoralSandoz Canada Incorporated2011-04-26Not applicableCanada
Sandoz Candesartantablet32 mgoralSandoz Canada Incorporated2014-03-19Not applicableCanada
Sandoz Candesartantablet16 mgoralSandoz Canada Incorporated2011-04-26Not applicableCanada
Sandoz Candesartantablet4 mgoralSandoz Canada Incorporated2011-04-26Not applicableCanada
Septa-candesartantablet16 mgoralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Septa-candesartantablet32 mgoralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Teva-candesartantablet32 mgoralTeva Canada Limited2012-06-01Not applicableCanada
Teva-candesartantablet8 mgoralTeva Canada Limited2012-06-01Not applicableCanada
Teva-candesartantablet16 mgoralTeva Canada Limited2012-06-01Not applicableCanada
Zinda-candesartantablet32 mgoralZinda Pharma LimitedNot applicableNot applicableCanada
Zinda-candesartantablet16 mgoralZinda Pharma LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-candesartantablet4 mgoralApotex Inc2011-04-26Not applicableCanada
Apo-candesartantablet8 mgoralApotex Inc2011-04-26Not applicableCanada
Apo-candesartantablet16 mgoralApotex Inc2011-04-26Not applicableCanada
Apo-candesartantablet32 mgoralApotex Inc2013-07-16Not applicableCanada
Candesartan Cilexetiltablet32 mg/1oralApotex Corp2014-01-13Not applicableUs
Candesartan Cilexetiltablet4 mg/1oralSandoz Inc2013-05-21Not applicableUs
Candesartan Cilexetiltablet4 mg/1oralApotex Corp2014-01-13Not applicableUs
Candesartan Cilexetiltablet16 mg/1oralAmerican Health Packaging2015-09-01Not applicableUs
Candesartan Cilexetiltablet8 mg/1oralSandoz Inc2013-05-21Not applicableUs
Candesartan Cilexetiltablet8 mg/1oralApotex Corp2014-01-13Not applicableUs
Candesartan Cilexetiltablet16 mg/1oralCarilion Materials Management2013-05-21Not applicableUs
Candesartan Cilexetiltablet16 mg/1oralSandoz Inc2013-05-21Not applicableUs
Candesartan Cilexetiltablet16 mg/1oralApotex Corp2014-01-13Not applicableUs
Candesartan Cilexetiltablet32 mg/1oralSandoz Inc2013-05-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AmiasEureco (Netherlands), Takeda (United Kingdom)
BlopressTakeda
Brand mixtures
NameLabellerIngredients
Act Candesartan/hctActavis Pharma Company
Apo-candesartan/hctzApotex Inc
Atacand HctAstra Zeneca Lp
Atacand PlusAstrazeneca Canada Inc
Auro-candesartan HctAuro Pharma Inc
Candesartan Cilexetil and HydrochlorothiazideMylan Pharmaceuticals Inc.
Candesartan Cilexetil and Hydrochlorothiazide TabletsAlembic Pharmaceuticals Limited
Candesartan Cilexetil-hydrochlorothiazidePar Pharmaceutical Inc.
Candesartan HctSivem Pharmaceuticals Ulc
Candesartan-hctzPro Doc Limitee
Candesartan/hctzSanis Health Inc
Ipg-candesartan + HctInternational Pharmaceutical Generics Ltd
Mylan-candesartan HctzMylan Pharmaceuticals Ulc
PMS-candesartan HctzPharmascience Inc
Sandoz Candesartan PlusSandoz Canada Incorporated
Septa-candesartan HctzSepta Pharmaceuticals Inc
Teva-candesartan/hctzTeva Canada Limited
Zinda-candesartan/hydrochlorothiazideZinda Pharma Limited
SaltsNot Available
Categories
UNIIS8Q36MD2XX
CAS number139481-59-7
WeightAverage: 440.454
Monoisotopic: 440.159688536
Chemical FormulaC24H20N6O3
InChI KeyInChIKey=HTQMVQVXFRQIKW-UHFFFAOYSA-N
InChI
InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
IUPAC Name
2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid
SMILES
CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • Benzimidazole
  • Phenylmethylamine
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
PharmacodynamicsCandesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionCandesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.
Related Articles
AbsorptionFollowing administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no affect on the bioavailability of candesartan from candesartan cilexetil.
Volume of distribution
  • 0.13 L/kg
Protein bindingCandesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
Metabolism

The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (<20%)occurs by O-deethylation via cytochrome P450 2C9 to form an inactive metabolite. Candesartan undergoes N-glucuronidation in the tetrazole ring by uridine diphosphate glucuronosyltransferase 1A3 (UGT1A3). O-glucuronidation may also occur. 75% of candesartan is excreted as unchanged drug in urine and feces.

SubstrateEnzymesProduct
Candesartan
O-Deethylated candesartanDetails
Candesartan
Candesartan N2-glucuronideDetails
Candesartan
Candesartan O-glucuronideDetails
Route of eliminationWhen candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).
Half lifeApproximately 9 hours.
Clearance
  • 0.37 mL/min/kg
ToxicityNo lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Candesartan Action PathwayDrug actionSMP00158
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8717
Caco-2 permeable-0.6208
P-glycoprotein substrateSubstrate0.5186
P-glycoprotein inhibitor INon-inhibitor0.848
P-glycoprotein inhibitor IINon-inhibitor0.9115
Renal organic cation transporterNon-inhibitor0.8266
CYP450 2C9 substrateNon-substrate0.7397
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6504
CYP450 1A2 substrateInhibitor0.5594
CYP450 2C9 inhibitorInhibitor0.5195
CYP450 2D6 inhibitorNon-inhibitor0.889
CYP450 2C19 inhibitorInhibitor0.5151
CYP450 3A4 inhibitorInhibitor0.7392
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testAMES toxic0.556
CarcinogenicityNon-carcinogens0.7561
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.5515 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.794
hERG inhibition (predictor II)Non-inhibitor0.5837
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca pharmaceuticals lp
Packagers
Dosage forms
FormRouteStrength
Tabletoral16 mg/1
Tabletoral32 mg/1
Tabletoral32 mg
Tabletoral4 mg/1
Tabletoral4 mg
Tabletoral8 mg/1
Tabletoral
Tabletoral16 mg
Tabletoral8 mg
Prices
Unit descriptionCostUnit
Atacand 30 4 mg tablet Bottle75.98USD bottle
Atacand 30 8 mg tablet Bottle74.96USD bottle
Atacand hct 32-25 mg tablet3.64USD tablet
Atacand hct 32-12.5 mg tablet3.43USD tablet
Atacand 32 mg tablet3.36USD tablet
Atacand hct 16-12.5 mg tablet3.36USD tablet
Atacand 16 mg tablet2.49USD tablet
Atacand 4 mg tablet2.44USD tablet
Atacand 8 mg tablet2.44USD tablet
Atacand 16 mg Tablet1.28USD tablet
Atacand 32 mg Tablet1.28USD tablet
Atacand 8 mg Tablet1.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2040955 No1998-02-032011-04-22Canada
CA2083305 No2003-12-092012-11-19Canada
US5534534 No1994-01-092014-01-09Us
US5705517 No1994-04-182011-04-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00771 mg/mLALOGPS
logP4.02ALOGPS
logP5.05ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)2.97ChemAxon
pKa (Strongest Basic)1.71ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity134.92 m3·mol-1ChemAxon
Polarizability45.35 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Marina Etinger, Boris Fedotev, Ben-Zion Dolitzky, “Preparation of candesartan cilexetil.” U.S. Patent US20050131037, issued June 16, 2005.

US20050131037
General References
  1. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66. [PubMed:13678868 ]
  2. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275 ]
  3. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650 ]
  4. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]
  5. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC09DA06C09DB07C09CA06
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (49.4 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Candesartan.
AbirateroneThe metabolism of Candesartan can be decreased when combined with Abiraterone.
AcebutololCandesartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Aceclofenac.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Candesartan.
AcetazolamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Candesartan is combined with Adapalene.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Candesartan.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Candesartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Candesartan.
AliskirenCandesartan may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Candesartan.
AlprenololCandesartan may increase the hypotensive activities of Alprenolol.
AmbrisentanCandesartan may increase the hypotensive activities of Ambrisentan.
AmifostineCandesartan may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Candesartan.
AmiodaroneThe metabolism of Candesartan can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Candesartan.
AmlodipineAmlodipine may increase the hypotensive activities of Candesartan.
AmobarbitalAmobarbital may increase the hypotensive activities of Candesartan.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Candesartan.
Amyl NitriteThe risk or severity of adverse effects can be increased when Candesartan is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Candesartan is combined with Antipyrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Candesartan.
ApraclonidineThe risk or severity of adverse effects can be increased when Candesartan is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Candesartan is combined with Apremilast.
AprepitantThe metabolism of Candesartan can be increased when combined with Aprepitant.
ArdeparinArdeparin may increase the hyperkalemic activities of Candesartan.
AripiprazoleAripiprazole may increase the hypotensive activities of Candesartan.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Candesartan.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Candesartan.
AtenololAtenolol may increase the hypotensive activities of Candesartan.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Candesartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Candesartan is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Candesartan is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Candesartan is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Candesartan.
BemiparinBemiparin may increase the hyperkalemic activities of Candesartan.
BenazeprilBenazepril may increase the hypotensive activities of Candesartan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Candesartan.
BenmoxinBenmoxin may increase the hypotensive activities of Candesartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Benoxaprofen.
BepridilCandesartan may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Candesartan.
BetaxololBetaxolol may increase the hypotensive activities of Candesartan.
BethanidineBethanidine may increase the hypotensive activities of Candesartan.
BimatoprostCandesartan may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Candesartan.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Candesartan.
BosentanBosentan may increase the hypotensive activities of Candesartan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Candesartan.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.
BretyliumCandesartan may increase the hypotensive activities of Bretylium.
BrimonidineCandesartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Candesartan.
BromfenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Candesartan.
BumetanideThe risk or severity of adverse effects can be increased when Candesartan is combined with Bumetanide.
BupranololCandesartan may increase the hypotensive activities of Bupranolol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Candesartan.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Candesartan.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Candesartan.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Candesartan.
CanagliflozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Canagliflozin.
CandoxatrilCandoxatril may increase the hypotensive activities of Candesartan.
CapecitabineThe metabolism of Candesartan can be decreased when combined with Capecitabine.
CaptoprilCandesartan may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Candesartan.
CarbamazepineThe metabolism of Candesartan can be increased when combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Candesartan.
CaroxazoneCaroxazone may increase the hypotensive activities of Candesartan.
CarprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Candesartan.
CarvedilolCandesartan may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Candesartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Celecoxib.
CeliprololCandesartan may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Candesartan can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Candesartan.
CertoparinCertoparin may increase the hyperkalemic activities of Candesartan.
ChloroquineThe risk or severity of adverse effects can be increased when Candesartan is combined with Chloroquine.
ChlorothiazideCandesartan may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Candesartan.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Candesartan.
CholecalciferolThe metabolism of Candesartan can be decreased when combined with Cholecalciferol.
CilazaprilCandesartan may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Candesartan.
CiprofloxacinCandesartan may increase the arrhythmogenic activities of Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Candesartan.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Candesartan.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Candesartan.
ClevidipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Candesartan.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Candesartan.
ClonidineClonidine may increase the hypotensive activities of Candesartan.
ClonixinThe risk or severity of adverse effects can be increased when Candesartan is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Candesartan.
ClotrimazoleThe metabolism of Candesartan can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Candesartan.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Candesartan.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Candesartan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Candesartan.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Candesartan.
CryptenamineCryptenamine may increase the hypotensive activities of Candesartan.
CyclosporineCandesartan may increase the hyperkalemic activities of Cyclosporine.
CyclosporineThe metabolism of Candesartan can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Candesartan.
D-LimoneneThe risk or severity of adverse effects can be increased when Candesartan is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Candesartan.
DabrafenibThe serum concentration of Candesartan can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Candesartan.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Candesartan.
DalteparinDalteparin may increase the hyperkalemic activities of Candesartan.
DapagliflozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candesartan.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Candesartan.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Candesartan.
DebrisoquinCandesartan may increase the hypotensive activities of Debrisoquin.
DelavirdineThe metabolism of Candesartan can be decreased when combined with Delavirdine.
DeserpidineCandesartan may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Candesartan.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Candesartan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Candesartan.
DiazoxideDiazoxide may increase the hypotensive activities of Candesartan.
DiclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Candesartan.
DiflunisalThe risk or severity of adverse effects can be increased when Candesartan is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Candesartan.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Candesartan.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Candesartan.
DiltiazemDiltiazem may increase the hypotensive activities of Candesartan.
DinutuximabThe risk or severity of adverse effects can be increased when Candesartan is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Candesartan.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Candesartan.
DorzolamideCandesartan may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Candesartan.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Candesartan.
DrospirenoneCandesartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Droxicam.
DuloxetineCandesartan may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Candesartan.
EfavirenzThe metabolism of Candesartan can be decreased when combined with Efavirenz.
EfonidipineCandesartan may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Candesartan.
EmpagliflozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Candesartan.
EnalaprilatCandesartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Candesartan.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Candesartan.
EpirizoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Candesartan.
EplerenoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Eplerenone.
EpoprostenolCandesartan may increase the hypotensive activities of Epoprostenol.
EprosartanCandesartan may increase the hypotensive activities of Eprosartan.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Candesartan.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Candesartan.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Candesartan.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Candesartan.
EstriolThe serum concentration of Estriol can be increased when it is combined with Candesartan.
EstroneThe serum concentration of Estrone can be increased when it is combined with Candesartan.
Etacrynic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Candesartan is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Candesartan.
EtodolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Candesartan is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Candesartan.
EtoricoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.
EtravirineThe metabolism of Candesartan can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Candesartan is combined with Evening primrose oil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Candesartan.
exisulindThe risk or severity of adverse effects can be increased when Candesartan is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Candesartan.
FelodipineCandesartan may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenbufen.
FenoldopamCandesartan may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenoprofen.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Candesartan.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Candesartan.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Candesartan.
FloctafenineThe risk or severity of adverse effects can be increased when Candesartan is combined with Floctafenine.
FloxuridineThe metabolism of Candesartan can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Candesartan can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Candesartan is combined with Flunixin.
FluorouracilThe metabolism of Candesartan can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Candesartan.
FluvastatinThe metabolism of Candesartan can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Candesartan can be decreased when combined with Fluvoxamine.
FosinoprilFosinopril may increase the hypotensive activities of Candesartan.
FosphenytoinThe metabolism of Candesartan can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Candesartan.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Candesartan.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Candesartan.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Candesartan.
GemfibrozilThe metabolism of Candesartan can be decreased when combined with Gemfibrozil.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Candesartan.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Candesartan.
GuanabenzGuanabenz may increase the hypotensive activities of Candesartan.
GuanadrelGuanadrel may increase the hypotensive activities of Candesartan.
GuanethidineCandesartan may increase the hypotensive activities of Guanethidine.
GuanfacineCandesartan may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Candesartan.
HeparinHeparin may increase the hyperkalemic activities of Candesartan.
HexamethoniumCandesartan may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Candesartan.
HMPL-004The risk or severity of adverse effects can be increased when Candesartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Candesartan.
HydralazineCandesartan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideCandesartan may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Candesartan.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Candesartan.
IbuprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Candesartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Candesartan is combined with Icatibant.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Candesartan.
IloprostIloprost may increase the hypotensive activities of Candesartan.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Candesartan.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Candesartan.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Candesartan.
IndapamideCandesartan may increase the hypotensive activities of Indapamide.
IndenololCandesartan may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Candesartan.
IndinavirThe metabolism of Candesartan can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Candesartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Indoprofen.
IndoraminCandesartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Candesartan.
IproniazidIproniazid may increase the hypotensive activities of Candesartan.
IrbesartanCandesartan may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Candesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candesartan.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Candesartan.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Candesartan.
KebuzoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Kebuzone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Candesartan.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Candesartan.
KetoconazoleThe metabolism of Candesartan can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Candesartan.
LacidipineCandesartan may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Candesartan.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Candesartan.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Candesartan.
LatanoprostLatanoprost may increase the hypotensive activities of Candesartan.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Candesartan.
LeflunomideThe risk or severity of adverse effects can be increased when Candesartan is combined with Leflunomide.
LeflunomideThe metabolism of Candesartan can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Candesartan.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Candesartan.
LercanidipineLercanidipine may increase the hypotensive activities of Candesartan.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Candesartan.
LevobunololThe risk or severity of adverse effects can be increased when Candesartan is combined with Levobunolol.
LevodopaCandesartan may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Candesartan.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Candesartan.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Candesartan.
LisinoprilLisinopril may increase the hypotensive activities of Candesartan.
LithiumThe serum concentration of Lithium can be increased when it is combined with Candesartan.
LofexidineCandesartan may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Candesartan.
LornoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Candesartan.
LovastatinThe metabolism of Candesartan can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Loxoprofen.
LumacaftorThe serum concentration of Candesartan can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Lumiracoxib.
MacitentanCandesartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate.
ManidipineCandesartan may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Candesartan.
MasoprocolThe risk or severity of adverse effects can be increased when Candesartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Candesartan.
MecamylamineMecamylamine may increase the hypotensive activities of Candesartan.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Candesartan.
MethohexitalMethohexital may increase the hypotensive activities of Candesartan.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Candesartan.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Candesartan.
MethyldopaCandesartan may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Candesartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candesartan.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Candesartan.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Candesartan.
MetipranololCandesartan may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Candesartan.
MetoprololMetoprolol may increase the hypotensive activities of Candesartan.
MibefradilCandesartan may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Candesartan.
MifepristoneThe serum concentration of Candesartan can be increased when it is combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Candesartan.
MinoxidilMinoxidil may increase the hypotensive activities of Candesartan.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Candesartan.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Candesartan.
MoclobemideMoclobemide may increase the hypotensive activities of Candesartan.
MoexiprilMoexipril may increase the hypotensive activities of Candesartan.
MolsidomineMolsidomine may increase the hypotensive activities of Candesartan.
MorphineThe serum concentration of Morphine can be increased when it is combined with Candesartan.
MoxonidineCandesartan may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabumetone.
NadololCandesartan may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Candesartan.
NaftifineThe risk or severity of adverse effects can be increased when Candesartan is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Candesartan.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Candesartan.
NaproxenThe risk or severity of adverse effects can be increased when Candesartan is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Candesartan is combined with NCX 4016.
NebivololCandesartan may increase the hypotensive activities of Nebivolol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Candesartan.
NepafenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Candesartan is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Candesartan.
NicardipineNicardipine may increase the hypotensive activities of Candesartan.
NicorandilNicorandil may increase the hypotensive activities of Candesartan.
NifedipineThe risk or severity of adverse effects can be increased when Candesartan is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Niflumic Acid.
NiguldipineCandesartan may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Candesartan.
NilvadipineCandesartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Candesartan is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Candesartan.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Candesartan.
NisoldipineNisoldipine may increase the hypotensive activities of Candesartan.
NitrendipineCandesartan may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Candesartan.
NitroprussideNitroprusside may increase the hypotensive activities of Candesartan.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Candesartan.
ObinutuzumabCandesartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Candesartan.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Candesartan.
OlmesartanOlmesartan may increase the hypotensive activities of Candesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.
OmapatrilatCandesartan may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Candesartan.
OmeprazoleThe metabolism of Candesartan can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Candesartan is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Candesartan.
OxaprozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.
OxprenololCandesartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Candesartan.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Candesartan.
PapaverineThe risk or severity of adverse effects can be increased when Candesartan is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Parecoxib.
PargylineCandesartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Candesartan.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Candesartan.
PenbutololCandesartan may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Candesartan.
PentoliniumCandesartan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candesartan.
PerindoprilPerindopril may increase the hypotensive activities of Candesartan.
PhenelzinePhenelzine may increase the hypotensive activities of Candesartan.
PheniprazinePheniprazine may increase the hypotensive activities of Candesartan.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Candesartan.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Candesartan.
PhenoxybenzamineCandesartan may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Candesartan.
PhentolaminePhentolamine may increase the hypotensive activities of Candesartan.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Phenylbutazone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Candesartan.
PhenytoinThe metabolism of Candesartan can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Candesartan is combined with Pimecrolimus.
PinacidilCandesartan may increase the hypotensive activities of Pinacidil.
PindololCandesartan may increase the hypotensive activities of Pindolol.
PirfenidoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Candesartan.
PiroxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Candesartan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Candesartan.
PolythiazideCandesartan may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Candesartan.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Candesartan.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Candesartan.
PrazosinPrazosin may increase the hypotensive activities of Candesartan.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Candesartan.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Candesartan.
PrimidonePrimidone may increase the hypotensive activities of Candesartan.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Candesartan.
PropacetamolThe risk or severity of adverse effects can be increased when Candesartan is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Candesartan.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Candesartan.
PTC299The risk or severity of adverse effects can be increased when Candesartan is combined with PTC299.
PyrimethamineThe metabolism of Candesartan can be decreased when combined with Pyrimethamine.
QuetiapineThe risk or severity of adverse effects can be increased when Candesartan is combined with Quetiapine.
QuinaprilCandesartan may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Candesartan.
QuinineQuinine may increase the hypotensive activities of Candesartan.
QuinineThe serum concentration of Quinine can be increased when it is combined with Candesartan.
RamiprilRamipril may increase the hypotensive activities of Candesartan.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Candesartan.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Candesartan.
RasagilineRasagiline may increase the hypotensive activities of Candesartan.
RemikirenRemikiren may increase the hypotensive activities of Candesartan.
RescinnamineCandesartan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Candesartan.
ResveratrolThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Candesartan.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Candesartan.
RifampicinThe metabolism of Candesartan can be increased when combined with Rifampicin.
RifapentineThe metabolism of Candesartan can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Candesartan.
RiociguatCandesartan may increase the hypotensive activities of Riociguat.
RisperidoneCandesartan may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Candesartan.
RituximabCandesartan may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Candesartan.
RofecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Rofecoxib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Candesartan.
SafrazineSafrazine may increase the hypotensive activities of Candesartan.
SalicylamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Candesartan is combined with Salsalate.
SaprisartanCandesartan may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Candesartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Candesartan.
SelegilineSelegiline may increase the hypotensive activities of Candesartan.
SelexipagCandesartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Candesartan is combined with Seratrodast.
SildenafilSildenafil may increase the antihypertensive activities of Candesartan.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Candesartan.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Candesartan.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Candesartan.
SitaxentanCandesartan may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Candesartan.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Candesartan.
SorafenibThe metabolism of Candesartan can be decreased when combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Candesartan.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Candesartan.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Candesartan.
SpiraprilCandesartan may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Candesartan.
SRT501The risk or severity of adverse effects can be increased when Candesartan is combined with SRT501.
SulfadiazineThe metabolism of Candesartan can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Candesartan can be decreased when combined with Sulfamethoxazole.
SulfasalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulfasalazine.
SulfisoxazoleThe metabolism of Candesartan can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Suprofen.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Candesartan.
TadalafilTadalafil may increase the antihypertensive activities of Candesartan.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Candesartan.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Candesartan.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Candesartan.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Candesartan.
TelmisartanCandesartan may increase the hypotensive activities of Telmisartan.
TemocaprilCandesartan may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Candesartan.
TenoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Candesartan is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Candesartan is combined with Teriflunomide.
TerlipressinCandesartan may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Candesartan.
ThiopentalThiopental may increase the hypotensive activities of Candesartan.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Tiaprofenic acid.
TiboloneCandesartan may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Candesartan.
TicagrelorThe metabolism of Candesartan can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Candesartan can be decreased when combined with Ticlopidine.
TicrynafenCandesartan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Candesartan.
TinzaparinTinzaparin may increase the hyperkalemic activities of Candesartan.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan.
TolazolineCandesartan may increase the hypotensive activities of Tolazoline.
TolbutamideThe metabolism of Candesartan can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Candesartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Candesartan.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Candesartan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Candesartan.
TorasemideTorasemide may increase the hypotensive activities of Candesartan.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Candesartan.
TrandolaprilTrandolapril may increase the hypotensive activities of Candesartan.
TranilastThe risk or severity of adverse effects can be increased when Candesartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Candesartan.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Candesartan.
TravoprostTravoprost may increase the hypotensive activities of Candesartan.
TreprostinilTreprostinil may increase the hypotensive activities of Candesartan.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Candesartan.
TrichlormethiazideCandesartan may increase the hypotensive activities of Trichlormethiazide.
TrimazosinCandesartan may increase the hypotensive activities of Trimazosin.
TrimethaphanCandesartan may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candesartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Candesartan is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Candesartan.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Candesartan.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Candesartan.
UnoprostoneCandesartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Valdecoxib.
Valproic AcidThe metabolism of Candesartan can be decreased when combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Candesartan.
VardenafilVardenafil may increase the antihypertensive activities of Candesartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Candesartan.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Candesartan.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Candesartan.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Candesartan.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Candesartan.
VoriconazoleThe metabolism of Candesartan can be decreased when combined with Voriconazole.
XylometazolineCandesartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Candesartan.
ZafirlukastThe metabolism of Candesartan can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Candesartan.
ZileutonThe risk or severity of adverse effects can be increased when Candesartan is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Candesartan is combined with Zomepirac.
Food Interactions
  • Administer on a regular basis, at about the same time each day.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Cervenka L, Navar LG: Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S197-201. [PubMed:9892163 ]
  3. Malmqvist K, Kahan T, Dahl M: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000 May;13(5 Pt 1):504-11. [PubMed:10826401 ]
  4. Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K: Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res. 1996 Jun;19(2):75-81. [PubMed:10968199 ]
  5. Engelhorn T, Doerfler A, Heusch G, Schulz R: Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett. 2006 Oct 2;406(1-2):92-6. Epub 2006 Aug 9. [PubMed:16901636 ]
  6. Caballero-George C, Vanderheyden PM, Solis PN, Gupta MP, Pieters L, Vauquelin G, Vlietinck A: In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor. Eur J Pharmacol. 2003 Jan 5;458(3):257-62. [PubMed:12504781 ]
  7. McInnes GT, O'Kane KP, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo HF: Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000 Apr;14(4):263-9. [PubMed:10805052 ]
  8. Vauquelin G, Fierens F, Van Liefde I: Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl. 2006 Mar;24(1):S23-30. [PubMed:16601569 ]
  9. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275 ]
  10. Meredith PA: Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin. 2007 Jul;23(7):1693-705. [PubMed:17588300 ]
  11. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. McClellan KJ, Goa KL: Candesartan cilexetil. A review of its use in essential hypertension. Drugs. 1998 Nov;56(5):847-69. [PubMed:9829158 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23